EyePoint, Inc.: announces topline data for LUCIA trial

What happened

• On Oct 19, 2026, EyePoint, Inc. issued a press release announcing topline data for LUCIA, one of its pivotal Phase 3 clinical trials evaluating DURAVYU™ for wet age-related macular degeneration (wet AMD).
• On Oct 19, 2026, the company posted an updated investor presentation on its website at www.eyepoint.bio.

Key details

• Date of filings and announcements: Oct 19, 2026.
• Trial name and phase: LUCIA, pivotal Phase 3.
• Product evaluated: DURAVYU™ for wet age-related macular degeneration (wet AMD).
• The Form 8-K was signed by George O. Elston, Executive Vice President and Chief Financial Officer.

Why it may matter

• The filing reports Item 8.01 "Other events," which covers the issuance of a press release announcing topline clinical trial data and the posting of an updated investor presentation.
• This filing does not show why the insider traded or why the company acted.